

Palivizumab (Synagis®)

Beneficiary Information				
1. Beneficiary Last Name: 2. First Name: 5. Beneficiary Gender: 3. Beneficiary ID #: 4. Beneficiary Date of Birth: 5. Beneficiary Gender:				
3. Beneficiary ID #:	4. Beneficiary Date of Birth:	5. Bo	eneficiary Gender:	
Prescriber Information				
6. Prescribing Provider NPI #:				
7. Requester Contact Information - Name:			Ext	
Drug Information				
8. Drug Name:	9. Strenath:	10. Quantity F	Per 30 Davs:	
11. Length of Therapy (in days): ☐ up to 30 □				
Clinical Information				
This is the beneficiary's \square first RSV season \square	☐ second RSV season			
Criteria for Infants younger than 12 mont				
1. Was the beneficiary born premature befo		n? □ YES □ NO		
Birth EGA: Weeks:				
Criteria for Infants less than 24 months of		Season with one of the follow	ring diagnoses	
2. Does the beneficiary have one of the follo				
☐ Hemodynamically significant acyanotic he		dication to control congestive		
heart failure, and will require cardiac surg				
☐ Moderate to severe pulmonary hyperten:				
☐ Neuromuscular disease or pulmonary abnormality that impairs the ability to clear secretions from the upper airways because of ineffective cough				
☐ Cyanotic heart disease, with cardiologist		nontation of cardiologist		
recommendation.	recommendation. Submit docum	nentation of cardiologist		
☐ Cystic Fibrosis with clinical evidence of CL	D and /or nutritional compromis	se		
□ Profoundly immunocompromised during RSV season				
☐ Undergoing cardiac transplantation durin				
☐ Chronic Lung Disease (CLD) of prematurit	_	2 weeks 0 days gestation and		
requiring greater than 21% oxygen for at		, 3		
**Please submit documentation of CLD as def	fined to meet criteria approval,	e.g. NICU discharge summary		
Criteria for Infants less than 24 months of age	AND in their SECOND RSV seas	on with one of the following diag	noses:	
3. Does the beneficiary have one of the follo	owing Diagnosis?			
☐ Profoundly immunocompromised during	RSV season			
☐ Cardiac transplantation during RSV seasor	n			
☐ Cystic Fibrosis with manifestations of seve	ere lung disease (previous hospit	alization for pulmonary		
exacerbation in first year or abnormalities		computed tomography that		
persist when stable) or weight-for-length	·			
☐ CLD of prematurity (see above definition)	·			
oxygen, chronic corticosteroid or diuretic therapy during the six-month period before start of second RSV season Indicate Treatment(s) for CLD: chronic corticosteroid therapy diuretic therapy				
supplemental oxygen no medical su		py \bigcirc diuretic therapy		
**Please submit documentation of CLD as of		val. e.g. NICU discharge summa	rv	
i icase submit accumentation of CLD as t	acimica to inicci criteria appro-	vai, cigi ivico disclidige sullilla	• 7	

Fax this form to: (833) 404-2393 Pharmacy PA Call Center: (833) 585-4309

https://www.covermymeds.com/main/prior-authorization-forms/



NOTE: The provider should use the Non-Covered State Medicaid Plan Services Request Form for Recipients under 21 Years of Age to request Synagis outside of policy criteria, for coverage outside the defined coverage period, if Beyfortus was administered during the current season, or if maternal vaccine Abrysvo was administered during pregnancy.

Signature of Prescriber:	Date:	
(Prescriber Signature I	Mandatory)	
I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification,		
omission, or concealment of material fact may subject me to	civil or criminal liability.	

Fax this form to: (833) 404-2393 Pharmacy PA Call Center: (833) 585-4309